Gabriel Brooks - 04 Feb 2026 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Signature
/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks
Issuer symbol
SLDB
Transactions as of
04 Feb 2026
Net transactions value
-$81,271
Form type
4
Filing time
06 Feb 2026, 17:59:08 UTC
Previous filing
02 Feb 2026
Next filing
18 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Brooks Gabriel Chief Medical Officer C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN /s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks 06 Feb 2026 0001997809

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Sale $81,271 -12,616 -13% $6.44 84,092 04 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.